Loyal Valley Capital

Portfolio Companies 2026 for Loyal Valley Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Loyal Valley Capital accounts for 16 tracked companies with verified cap-table data, 16 of which disclose round sizes totalling $3.7B. The median disclosed raise is $180M, and the largest is Abogen Biosciences at $700M, ahead of Gaosi Education Group ($407M) and Zhaoke Ophthalmology Pharmaceutical ($395M).

The names that recur most often on these portfolio cap tables are Loyal Valley Capital (16 companies), Lilly Asia Ventures (3 companies), IDG Capital (3 companies), OrbiMed (2 companies), Qiming Venture Partners (2 companies), Apricot Capital (2 companies). By latest disclosed round, the market skews Series D (4), Series B (3), Series C (2), IPO (2).

Best funded Loyal Valley Capital companies

  1. Abogen Biosciences — $700M (latest: Series C)
  2. Gaosi Education Group — $407M (latest: Series D)
  3. Zhaoke Ophthalmology Pharmaceutical — $395M (latest: IPO)
  4. Mabwell Biotech — $300M (latest: Series A)
  5. JIANGXIAOBAI — $300M (latest: Series E)
  6. ABclonal — $282M (latest: Series D)
  7. DP Technology — $258M (latest: Series C)
  8. Surgerii Technology — $180M (latest: Series D)
  9. Sinovent — $145M (latest: Series E)
  10. Chabaidao — $140M (latest: IPO)
  11. EdiGene — $129M (latest: Series B)
  12. Medilink Therapeutics — $120M (latest: Series B)
  13. Remegen — $100M
  14. Teligene — $93M
  15. Regor Therapeutics — $90M (latest: Series B)

Loyal Valley Capital — related firms and companies (56)

Loyal Valley Capital alternatives · All research reports